|
1
|
Lee S and Schmitt CA: The dynamic nature
of senescence in cancer. Nat Cell Biol. 21:94–101. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rodier F, Coppé J, Patil CK, Hoeijmakers
WA, Muñoz DP, Raza SR, Freund A, Campeau E, Davalos AR and Campisi
J: Persistent DNA damage signalling triggers senescence-associated
inflammatory cytokine secretion. Nat Cell Biol. 11:973–979. 2009.
View Article : Google Scholar :
|
|
3
|
Beauséjour CM, Krtolica A, Galimi F,
Narita M, Lowe SW, Yaswen P and Campisi J: Reversal of human
cellular senescence: Roles of the p53 and p16 pathways. EMBO J.
22:4212–4222. 2003. View Article : Google Scholar :
|
|
4
|
Kuilman T and Peeper DS:
Senescence-messaging secretome: SMS-ing cellular stress. Nat Rev
Cancer. 9:81–94. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
te Poele RH, Okorokov AL, Jardine L,
Cummings J and Joel SP: DNA damage is able to induce senescence in
tumor cells in vitro and in vivo. Cancer Res. 62:1876–1883.
2002.PubMed/NCBI
|
|
6
|
Narita M, Nũnez S, Heard E, Narita M, Lin
AW, Hearn SA, Spector DL, Hannon GJ and Lowe SW: Rb-mediated
hetero-chromatin formation and silencing of E2F target genes during
cellular senescence. Cell. 113:703–716. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vétillard A, Jonchère B, Moreau M, Toutain
B, Henry C, Fontanel S, Bernard AC, Campone M, Guette C and
Coqueret O: Akt inhibition improves irinotecan treatment and
prevents cell emergence by switching the senescence response to
apoptosis. Oncotarget. 6:43342–43362. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jonchère B, Vétillard A, Toutain B, Lam D,
Bernard AC, Henry C, De Carné Trécesson S, Gamelin E, Juin P,
Guette C and Coqueret O: Irinotecan treatment and senescence
failure promote the emergence of more transformed and invasive
cells that depend on anti-apoptotic Mcl-1. Oncotarget. 6:409–426.
2015. View Article : Google Scholar
|
|
9
|
Besson D, Pavageau AH, Valo I, Bourreau A,
Bélanger A, Eymerit-Morin C, Moulière A, Chassevent A,
Boisdron-Celle M, Morel A, et al: A quantitative proteomic approach
of the different stages of colorectal cancer establishes OLFM4 as a
new nonmetastatic tumor marker. Mol Cell Proteomics.
10:M111.0097122011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Campone M, Valo I, Jézéquel P, Moreau M,
Boissard A, Campion L, Loussouarn D, Verriele V, Coqueret O and
Guette C: Prediction of recurrence and survival for triple-negative
breast cancer (TNBC) by a protein signature in tissue samples. Mol
Cell Proteomics. 14:2936–2946. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Persson S, Rosenquist M, Knoblach B,
Khosravi-Far R, Sommarin M and Michalak M: Diversity of the protein
disulfide isomerase family: Identification of breast tumor induced
Hag2 and Hag3 as novel members of the protein family. Mol
Phylogenet Evol. 36:734–740. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Park SW, Zhen G, Verhaeghe C, Nakagami Y,
Nguyenvu LT, Barczak AJ, Killeen N and Erle DJ: The protein
disulfide isomerase AGR2 is essential for production of intestinal
mucus. Proc Natl Acad Sci. 106:6950–6955. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Delom F, Mohtar MA, Hupp T and Fessart D:
The anterior gradient-2 interactome. Am J Physiol Cell Physiol.
318:C40–C47. 2020. View Article : Google Scholar
|
|
14
|
Delom F, Nazaraliyev A and Fessart D: The
role of protein disulphide isomerase AGR2 in the tumour niche. Biol
Cell. 110:271–282. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fessart D, Domblides C, Avril T, Eriksson
LA, Begueret H, Pineau R, Malrieux C, Dugot-Senant N, Lucchesi C,
Chevet E and Delom F: Secretion of protein disulphide isomerase
AGR2 confers tumorigenic properties. Elife. 5:e138872016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fessart D, de Barbeyrac C, Boutin I,
Grenier T, Richard E, Begueret H, Bernard D, Chevet E, Robert J and
Delom F: Extracellular AGR2 triggers lung tumour cell proliferation
through repression of p21CIP1. Biochim Biophys Acta Mol Cell Res.
1868:1189202021. View Article : Google Scholar
|
|
17
|
Maurel M, Obacz J, Avril T, Ding YP,
Papadodima O, Treton X, Daniel F, Pilalis E, Hörberg J, Hou W, et
al: Control of anterior GRadient 2 (AGR2) dimerization links
endoplasmic reticulum proteostasis to inflammation. EMBO Mol Med.
11:e101202019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Aberger F, Weidinger G, Grunz H and
Richter K: Anterior specification of embryonic ectoderm: The role
of the Xenopus cement gland-specific gene XAG-2. Mech Dev.
72:115–130. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang JS, Gong A, Cheville JC, Smith DI
and Young CYF: AGR2, an androgen-inducible secretory protein
overexpressed in prostate cancer. Genes Chromosomes Cancer.
43:249–259. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Thompson DA and Weigel RJ: hAG-2, the
human homologue of thexenopus laeviscement gland gene XAG-2, is
coexpressed with estrogen receptor in breast cancer cell lines.
Biochem Biophys Res Commun. 251:111–116. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ramachandran V, Arumugam T, Wang H and
Logsdon CD: Anterior gradient 2 is expressed and secreted during
the development of pancreatic cancer and promotes cancer cell
survival. Cancer Res. 68:7811–7818. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pizzi M, Fassan M, Balistreri M,
Galligioni A, Rea F and Rugge M: Anterior gradient 2 overexpression
in lung adenocarcinoma. Appl Immunohistochem Mol Morphol. 20:31–36.
2012. View Article : Google Scholar
|
|
23
|
Chevet E, Fessart D, Delom F, Mulot A,
Vojtesek B, Hrstka R, Murray E, Gray T and Hupp T: Emerging roles
for the pro-oncogenic anterior gradient-2 in cancer development.
Oncogene. 32:2499–2509. 2013. View Article : Google Scholar
|
|
24
|
Salmans ML, Zhao F and Andersen B: The
estrogen-regulated anterior gradient 2 (AGR2) protein in breast
cancer: A potential drug target and biomarker. Breast Cancer Res.
15:2042013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hrstka R, Nenutil R, Fourtouna A, Maslon
MM, Naughton C, Langdon S, Murray E, Larionov A, Petrakova K,
Muller P, et al: The pro-metastatic protein anterior gradient-2
predicts poor prognosis in tamoxifen-treated breast cancers.
Oncogene. 29:4838–4847. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vanderlaag KE, Hudak S, Bald L,
Fayadat-Dilman L, Sathe M, Grein J and Janatpour MJ: Anterior
gradient-2 plays a critical role in breast cancer cell growth and
survival by modulating cyclin D1, estrogen receptor-alpha and
survivin. Breast Cancer Res. 12:R322010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu D, Rudland PS, Sibson DR,
Platt-Higgins A and Barraclough R: Human homologue of cement gland
protein, a novel metastasis inducer associated with breast
carcinomas. Cancer Res. 65:3796–3805. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hrstka R, Brychtova V, Fabian P, Vojtesek
B and Svoboda M: AGR2 predicts tamoxifen resistance in
postmenopausal breast cancer patients. Dis Markers. 35:207–212.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li Z, Zhu Q, Hu L, Chen H, Wu Z and Li D:
Anterior gradient 2 is a binding stabilizer of hypoxia inducible
factor-1a that enhances CoCl 2-induced doxorubicin resistance in
breast cancer cells. Cancer Sci. 106:1041–1049. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Higa A, Mulot A, Delom F, Bouchecareilh M,
Nguyên DT, Boismenu D, Wise MJ and Chevet E: Role of pro-oncogenic
protein disulfide isomerase (PDI) family member anterior gradient 2
(AGR2) in the control of endoplasmic reticulum homeostasis. J Biol
Chem. 286:44855–44868. 2011. View Article : Google Scholar
|
|
31
|
Dimri GP, Lee X, Basile G, Acosta M, Scott
G, Roskelley C, Medrano EE, Linskens M, Rubelj I and Pereira-Smith
O: A biomarker that identifies senescent human cells in culture and
in aging skin in vivo. Proc Natl Acad Sci USA. 92:9363–9367. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Vindeløv LL, Christensen IJ and Nissen NI:
A Detergent-trypsin method for the preparation of nuclei for flow
cytometric DNA analysis. Cytometry. 3:323–327. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gillet LC, Navarro P, Tate S, Röst H,
Selevsek N, Reiter L, Bonner R and Aebersold R: Targeted data
extraction of the MS/MS spectra generated by data-independent
acquisition: A new concept for consistent and accurate proteome
analysis. Mol Cell Proteomics. 11:0111.0167172012. View Article : Google Scholar
|
|
34
|
Perez-Riverol Y, Csordas A, Bai J,
Bernal-Llinares M, Hewapathirana S, Kundu DJ, Inuganti A, Griss J,
Mayer G, Eisenacher M, et al: The PRIDE database and related tools
and resources in 2019: Improving support for quantification data.
Nucleic Acids Res. 47:D442–D450. 2019. View Article : Google Scholar :
|
|
35
|
Innes HE, Liu D, Barraclough R, Davies
MPA, O'Neill PA, Platt-Higgins A, de Silva Rudland S, Sibson DR and
Rudland PS: Significance of the metastasis-inducing protein AGR2
for outcome in hormonally treated breast cancer patients. Br J
Cancer. 94:1057–1065. 2006. View Article : Google Scholar
|
|
36
|
Tang W, Zhou M, Dorsey TH, Prieto DA, Wang
XW, Ruppin E, Veenstra TD and Ambs S: Integrated
proteotranscriptomics of breast cancer reveals globally increased
protein-mRNA concordance associated with subtypes and survival.
Genome Med. 10:942018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Guillon J, Petit C, Moreau M, Toutain B,
Henry C, Roché H, Bonichon-Lamichhane N, Salmon JP, Lemonnier J,
Campone M, et al: Regulation of senescence escape by TSP1 and CD47
following chemotherapy treatment. Cell Death Dis. 10:1992019.
View Article : Google Scholar :
|
|
38
|
Pohler E, Craig AL, Cotton J, Lawrie L,
Dillon JF, Ross P, Kernohan N and Hupp TR: The barrett's antigen
anterior gradient-2 silences the p53 transcriptional response to
DNA damage. Mol Cell Proteomics. 3:534–547. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hrstka R, Bouchalova P, Michalova E,
Matoulkova E, Muller P, Coates PJ and Vojtesek B: AGR2 oncoprotein
inhibits p38 MAPK and p53 activation through a DUSP10-mediated
regulatory pathway. Mol Oncol. 10:652–662. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Valo I, Raro P, Boissard A, Maarouf A,
Jézéquel P, Verriele V, Campone M, Coqueret O and Guette C: OLFM4
expression in ductal carcinoma in situ and in invasive breast
cancer cohorts by a SWATH-based proteomic approach. Proteomics.
19:e18004462019. View Article : Google Scholar
|
|
41
|
Laplante M and Sabatini DM: MTOR signaling
in growth control and disease. Cell. 149:274–293. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yang G, Murashige DS, Humphrey SJ and
James DE: A positive feedback loop between akt and mTORC2 via SIN1
phosphorylation. Cell Rep. 12:937–943. 2015. View Article : Google Scholar
|
|
43
|
Sarbassov DD, Guertin DA, Ali SM and
Sabatini DM: Phosphorylation and regulation of Akt/PKB by the
rictor-mTOR complex. Science. 307:1098–1101. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Iannello A, Thompson TW, Ardolino M, Lowe
SW and Raulet DH: p53-dependent chemokine production by senescent
tumor cells supports NKG2D-dependent tumor elimination by natural
killer cells. J Exp Med. 210:2057–2069. 2013. View Article : Google Scholar :
|
|
45
|
Dahal Lamichane B, Jung SY, Yun J, Kang S,
Kim DY, Lamichane S, Kim YJ, Park JH, Jang WB, Ji ST, et al: AGR2
is a target of canonical Wnt/β-catenin signaling and is important
for stemness maintenance in colorectal cancer stem cells. Biochem
Biophys Res Commun. 515:600–606. 2019. View Article : Google Scholar
|
|
46
|
Arumugam T, Deng D, Bover L, Wang H,
Logsdon CD and Ramachandran V: New blocking antibodies against
novel AGR2-C4 4A pathway reduce growth and metastasis of pancreatic
tumors and increase survival in mice. Mol Cancer Ther. 14:941–951.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Armes JE, Davies CM, Wallace S, Taheri T,
Perrin LC and Autelitano DJ: AGR2 expression in ovarian tumours: A
potential biomarker for endometrioid and mucinous differentiation.
Pathology. 45:49–54. 2013. View Article : Google Scholar
|
|
48
|
Hu Z, Gu Y, Han B, Zhang J, Li Z, Tian K,
Young CYF and Yuan H: Knockdown of AGR2 induces cellular senescence
in prostate cancer cells. Carcinogenesis. 33:1178–1186. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hrstka R, Murray E, Brychtova V, Fabian P,
Hupp TR and Vojtesek B: Identification of an AKT-dependent
signalling pathway that mediates tamoxifen-dependent induction of
the pro-metastatic protein anterior. Cancer Lett. 333:187–193.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Liu Q, Li Y and Yao L: Knockdown of AGR2
induces cell apoptosis and reduces chemotherapy resistance of
pancreatic cancer cells with the involvement of ERK/AKT axis.
Pancreatology. 18:678–688. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Dong A, Gupta A, Pai RK, Tun M and Lowe
AW: The human adenocarcinoma-associated gene, AGR2, induces
expression of amphiregulin through hippo pathway co-activator YAP1
activation. J Biol Chem. 286:18301–18310. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Matoulkova E, Sommerova L, Pastorek M,
Vojtesek B and Hrstka R: Regulation of AGR2 expression via 3′UTR
shortening. Exp Cell Res. 356:40–47. 2017.PubMed/NCBI
|
|
53
|
Tiemann K, Garri C, Lee SB, Malihi PD,
Park M, Alvarez RM, Yap LP, Mallick P, Katz JE, Gross ME and Kani
K: Loss of ER retention motif of AGR2 can impact mTORC signaling
and promote cancer metastasis. Oncogene. 38:3003–3018. 2019.
View Article : Google Scholar
|
|
54
|
Dumartin L, Alrawashdeh W, Trabulo SM,
Radon TP, Steiger K, Feakins RM, di Magliano MP, Heeschen C,
Esposito I, Lemoine NR and Crnogorac-Jurcevic T: ER stress protein
AGR2 precedes and is involved in the regulation of pancreatic
cancer initiation. Oncogene. 36:3094–3103. 2017. View Article : Google Scholar :
|
|
55
|
Zhao F, Edwards R, Dizon D, Afrasiabi K,
Mastroianni JR, Geyfman M, Ouellette AJ, Andersen B and Lipkin SM:
Disruption of Paneth and goblet cell homeostasis and increased
endoplasmic reticulum stress in Agr2-/-mice. Dev Biol. 338:270–279.
2010. View Article : Google Scholar
|
